London, UK – 3 November 2021 COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, today ...

COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the results from ...

COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced that its ...

Compass Pathways has filed paperwork for a Nasdaq IPO that will tee it up to take psilocybin therapy COMP360 through midphase development. Compass is developing psilocybin, the active ingredient in ...

As COMPASS Pathways (NASDAQ:CMPS) crunches more data from a recent trial investigating psilocybin therapy for treatment-resistant depression (TRD), findings show that a higher dose of 25mg (compared ...

LONDON & MORRISVILLE, N.C.--(BUSINESS WIRE)--COMPASS Pathways, a healthcare company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it is ...

COMPASS Pathways' CMPS Phase 2b study of synthetic psilocybin COMP360 paired with psychological support for Treatment-Resistant Depression (TRD) is still nourishing the psychedelics research field, as ...

Struggling with anxiety, depression, trauma, relationship challenges, or feeling stuck in life? Perhaps you're overwhelmed by stress, navigating a major life transition, or finding it difficult to ...

Compass Therapy offers a wide range of psychotherapy, counseling, and social skills training services. We offer services for adults, children, couples, and families. We can also help with anxiety ...

Compass Pathways (CMPS) added ~20% in the premarket on Tuesday after the U.K.-based biotech announced that its psychedelic therapy COMP360 reached the primary endpoint in a late-stage trial for ...

The FDA has awarded Compass Pathways a National Priority Voucher for its COMP360 psilocybin therapy for treatment-resistant depression, cutting potential review time to one or two months after filing.

Compass Pathways Plc fell the most since its listing last year after results from an experimental therapy based on psilocybin, or so-called magic mushrooms, fueled investor concerns about the ...